{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:56Z","timestamp":1787962316629,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Thiopurines are the prerequisite for immunomodulation in inflammatory bowel disease (IBD) therapy. When administered in high (oncological) dose, thiopurine metabolites act as purine antagonists, causing DNA-strand breakage and myelotoxicity. In lower IBD dosages, the mode of action is primarily restricted to anti-inflammatory effects. Then, myelosuppression and hepatotoxicity are the most common adverse events of thiopurines. The aim of this study was to assess the effect of thiopurine metabolites on hematologic and hepatic parameters and to determine which patient characteristics are related to generation of thiopurine metabolites.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The authors scrutinized the therapeutic drug monitoring database of the VU University medical center and subsequently merged this database with the Clinical Laboratory database of our hospital covering the same time period (2010\u20132015).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The authors included 940 laboratory findings of 424 unique patients in this study. Concentrations of 6-thioguanine nucleotides (6-TGN) correlated negatively with red blood cell count, white blood cell count, and neutrophil count in both azathioprine (AZA) and mercaptopurine users. There was a positive correlation with mean corpuscular volume. In patients using 6-thioguanine, 6-TGN concentrations correlated positively with white blood cell count. Furthermore, there was an inverse correlation between patient's age and 6-TGN concentrations in patients using AZA or 6-thioguanine, and we observed an inverse correlation between body mass index and 6-TGN concentrations in patients using AZA or mercaptopurine. No relations were observed with liver test abnormalities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Thiopurine derivative therapy influenced bone marrow production and the size of red blood cells. Age and body mass index were important pharmacokinetic factors in the generation of 6-TGN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000414","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T15:22:41Z","timestamp":1494343361000},"page":"399-405","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study"],"prefix":"10.1097","volume":"39","author":[{"given":"Berrie","family":"Meijer","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham J.","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, VU University Medical Center, Amsterdam; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J. J.","family":"Mulder","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Bouma","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"van Bodegraven","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology and"},{"name":"Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Center, Heerlen-Sittard-Geleen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne K. H.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2174\/138920009790711887","article-title":"On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance","volume":"10","author":"Van Asseldonk","year":"2009","journal-title":"Curr Drug Metab."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1440-1746.2005.03832.x","article-title":"Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease","volume":"20","author":"Gearry","year":"2005","journal-title":"J Gastroenterol Hepatol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FPC.0b013e328334338f","article-title":"Thiopurine pathway","volume":"20","author":"Zaza","year":"2010","journal-title":"Pharmacogenet Genomics."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/FTD.0000000000000326","article-title":"Rac1 as a potential pharmacodynamic biomarker for thiopurine therapy in inflammatory bowel disease","volume":"38","author":"Seinen","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40291-016-0232-1","article-title":"Rac attack: modulation of the small GTPase Rac in inflammatory bowel disease and thiopurine therapy","volume":"20","author":"Seinen","year":"2016","journal-title":"Mol Diagn Ther."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/ncpgasthep1000","article-title":"Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD","volume":"4","author":"de Boer","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.170.10.4986","article-title":"Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides","volume":"170","author":"Quemeneur","year":"2003","journal-title":"J Immunol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00008571-200208000-00003","article-title":"Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism","volume":"12","author":"Schwab","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","article-title":"Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience","volume":"34","author":"Connell","year":"1993","journal-title":"Gut"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jgh.13656","article-title":"6-methylmercaptopurine induced leukocytopenia during thiopurine therapy in IBD patients","volume":"32","author":"Meijer","year":"2017","journal-title":"J Gastroenterol Hepatol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1373\/clinchem.2005.050831","article-title":"Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine\/6-mercaptopurine therapy","volume":"51","author":"Dervieux","year":"2005","journal-title":"Clin Chem."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jchromb.2010.03.004","article-title":"Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise","volume":"878","author":"de Graaf","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0378-4347(92)80347-S","article-title":"High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample","volume":"583","author":"Lennard","year":"1992","journal-title":"J Chromatogr."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1373\/49.2.260","article-title":"Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods","volume":"49","author":"Shipkova","year":"2003","journal-title":"Clin Chem."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-002-0442-6","article-title":"Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia","volume":"50","author":"Lancaster","year":"2002","journal-title":"Cancer Chemother Pharmacol."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/MEG.0000000000000675","article-title":"Usefulness of mean corpuscular volume as a surrogate marker for monitoring thiopurine treatment in inflammatory bowel disease","volume":"28","author":"Dujardin","year":"2016","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/MIB.0000000000000302","article-title":"Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC","volume":"21","author":"Bouguen","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5414\/CPP48275","article-title":"High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine","volume":"48","author":"Nguyen","year":"2010","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s10620-014-3362-5","article-title":"Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD","volume":"60","author":"Kopylov","year":"2015","journal-title":"Dig Dis Sci."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0399-8320(05)82219-5","article-title":"RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine","volume":"29","author":"D'Halluin","year":"2005","journal-title":"Gastroenterol Clin Biol."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/imj.12915","article-title":"Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?","volume":"46","author":"Heerasing","year":"2016","journal-title":"Intern Med J."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ecco-jcc\/jjv084","article-title":"Body mass index and smoking affect thioguanine nucleotide levels in inflammatory bowel disease","volume":"9","author":"Poon","year":"2015","journal-title":"J Crohns Colitis."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10620-009-0846-9","article-title":"Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients","volume":"55","author":"Holtmann","year":"2010","journal-title":"Dig Dis Sci."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.12616","article-title":"Systematic review with meta-analysis: inflammatory bowel disease in the elderly","volume":"39","author":"Gisbert","year":"2014","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:12:22Z","timestamp":1692051142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000414","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}